首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL3 |
| Uniprot No | P19876 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-107aa |
| 氨基酸序列 | ASVVTELRCQCLQTLQGIHLKNIQSVNVRSPGPHCAQTEVIATLKNGKKA CLNPASPMVQKIIEKILNKGSTN |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL3重组蛋白的3篇模拟参考文献示例(文献信息为虚构，仅供格式参考)：
---
1. **文献名称**: *Recombinant CXCL3 promotes neutrophil migration and exacerbates skin inflammation in a murine model*
**作者**: Li H, Wang T, Chen R
**摘要**: 该研究通过大肠杆菌表达系统制备重组CXCL3蛋白，并验证其趋化活性。在小鼠皮肤炎症模型中，局部注射重组CXCL3显著增强了中性粒细胞的浸润，表明CXCL3可能通过调控中性粒细胞迁移参与炎症反应。
---
2. **文献名称**: *Expression and functional characterization of CXCL3 in colorectal cancer progression*
**作者**: Zhang Y, Liu X, Zhou M
**摘要**: 研究团队通过哺乳动物细胞表达系统获得高纯度重组CXCL3蛋白，并发现其通过激活ERK信号通路促进结直肠癌细胞的侵袭和转移。体外实验表明，CXCL3重组蛋白可诱导肿瘤微环境中基质细胞的活化。
---
3. **文献名称**: *CXCL3 recombinant protein enhances angiogenesis via CXCR2-dependent pathways*
**作者**: Kim S, Park J, Lee D
**摘要**: 该文献报道了重组CXCL3蛋白在血管生成中的作用。通过体外内皮细胞管腔形成实验和小鼠体内基质胶栓模型，证实CXCL3通过结合CXCR2受体激活VEGF通路，促进新生血管形成。
---
4. **文献名称**: *Optimization of CXCL3 recombinant protein production in Pichia pastoris and its anti-bacterial role*
**作者**: Müller F, Schmidt B
**摘要**: 研究利用毕赤酵母系统高效表达重组CXCL3蛋白，优化了发酵条件以提高产量。功能实验显示，该蛋白能增强巨噬细胞对细菌的吞噬能力，提示其在先天免疫中的潜在应用价值。
---
注：以上文献为模拟内容，实际引用时请以真实发表的论文为准。如需查找真实文献，建议在PubMed或Web of Science中以“CXCL3 recombinant protein”为关键词检索。
CXCL3 (C-X-C motif chemokine ligand 3), also known as GROγ or MIP-2β, is a small secretory protein belonging to the CXC chemokine family. It is encoded by the CXCL3 gene in humans and shares structural homology with CXCL1 and CXCL2. forming a gene cluster on chromosome 4q21. Functionally, CXCL3 acts as a chemoattractant for neutrophils by binding to the G-protein-coupled receptor CXCR2. mediating immune cell migration during inflammation, wound healing, and infection. Its expression is induced by pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and pathogen-associated molecular patterns through NF-κB signaling pathways.
Recombinant CXCL3 protein is produced via genetic engineering in systems like Escherichia coli or mammalian cells, ensuring high purity and bioactivity. The protein typically retains conserved cysteine residues critical for its tertiary structure and receptor interaction. Researchers utilize recombinant CXCL3 to study its role in diseases such as cancer, where it promotes angiogenesis, tumor growth, and metastasis by recruiting immunosuppressive cells or activating oncogenic pathways. It is also implicated in chronic inflammatory conditions like arthritis and psoriasis.
In drug development, recombinant CXCL3 serves as a tool for screening antagonists or neutralizing antibodies targeting the CXCR2/CXCL3 axis. Quality control involves endotoxin testing, mass spectrometry validation, and functional assays (e.g., chemotaxis assays). Despite its pathological roles, CXCL3’s dual functions in immune regulation and tissue repair highlight its therapeutic potential, driving ongoing research into context-specific modulation strategies.
×
